Naringenin Protects against Hypertension by Regulating Lipid Disorder and Oxidative Stress in a Rat Model

Abstract

Background: Naringenin, a natural resource-derived flavanone, exhibits a plethora of pharmacological properties. The present study aimed to investigate the effects of Naringenin on obesity-associated hypertension and its underlying mechanism. Methods: Obesity-associated hypertension rat model was established with a high-fat diet (HFD) and was administrated with Naringenin (25, 50, 100 mg/kg). Body and fat weight were recorded and blood pressure was measured. Serum lipid parameters (cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides), oxidative stress biomarkers (malondialdehyde (MDA), superoxide dismutase (SOD), nitrite oxide (NO), and glutathione (GSH)), and adipocytokines (leptin and adiponectin) were determined. The expressions of signal transducer and activator of transcription (STAT) 3 were determined by using Western blotting. Results: Treatment with Naringenin (100 mg/kg) reduced body and fat weight in HFD-induced rats. Besides, treatment with Naringenin (50 and 100 mg/kg) reduced blood pressure and regulated lipid parameters by decreasing cholesterol, triglycerides, and LDL and increasing HDL. Treatment with Naringenin (50 and 100 mg/kg) reduced serum MDA and NO, whereas increased serum SOD and GSH. Furthermore, Treatment with Naringenin (50 and 100 mg/kg) regulated adipocytokines and decreased the phosphorylation of STAT3. Conclusion: Naringenin ameliorates obesity-associated hypertension by regulating lipid disorder and oxidative stress.

Analyses of Physical and Chemical Compositions of Different Medicinal Specifications of CRPV by Use of Multiple Instrumental Techniques Combined with Multivariate Statistical Analysis

“…Among them, the flavanone aglycones, naringenin and hesperetin, were the unique components of GQP. Naringenin can reduce the phosphorylation of STAT3 in the hypothalamus by regulating adipocytokines, to achieve weight loss in obese rats and treat hypertension [ 42 ]. In vitro and in vivo experiments have confirmed that naringenin can reduce hepatic lipid accumulation and attenuate the inflammation in mice by downregulating the expression of the NLRP3 /NF-κB signaling pathway both in Kupffer cells and hepatocytes [ 43 ].…”

Deciphering the mechanisms of Yinlan Tiaozhi capsule in treating hyperlipidemia by combining network pharmacology, molecular docking and experimental verification

“…Naringenin has an antioxidative activity to relieve oxidative stress, alleviate IR, and inhibit the production of inflammatory mediators 35 , 36 . It has been shown that naringenin prevents HLP, IR, and atherosclerosis by decreasing TC, TG, and LDL and increasing HDL 37 . In addition, naringenin inhibited fibroblast activation and inflammatory cell recruitment.…”

Banxia baizhu tianma decoction, a Chinese herbal formula, for hypertension: Integrating meta-analysis and network pharmacology

“…Studies have shown that naringenin exerts antihypertensive effects by attenuating the MCR/ACE/KIM-1 pathway (Oyagbemi et al, 2020). Recently, Liu et al found that naringenin can reduce weight, fat, and blood pressure in obesity-associated hypertension rats, and the mechanism is related to the regulation of lipid disorders and oxidative stress (Liu et al, 2022). Eburicoic acid is present in the polyporus.…”